Specifically, the guidelines recommend that men be adequately informed and educated about prostate cancer risks and screening, discuss with their healthcare providers the benefits and limitations of PSA testing, and make an informed personal choice, based on the patient’s own values and preferences, about whether to be screened. The gene discussed is KLK3; the disease is prostate carcinoma.